RevBio, Inc.
RevBio, Inc. is a clinical stage medical device company focused on developing and commercializing TETRANITE®, a patented synthetic bone adhesive biomaterial. The company aims to transform bone repair across various applications in both human and animal health, leveraging innovative technology inspired by natural materials.
RevBio, Inc.
Patents
Implantable objects, guiding devices, and methods of use thereof
2023-09-19 • US-11759546-B2
View Details
Implantable objects, guiding devices, and methods of use thereof
2023-09-19 • US-11759546-B2
View DetailsWhat We Do
A patented, synthetic, injectable, self-setting, load-bearing, and osteoconductive bone adhesive biomaterial that bonds bone to bone and bone to metal. It is designed for use in dental and orthopedic applications, with ongoing clinical trials to validate its efficacy.
A patented, synthetic, injectable, self-setting, load-bearing, and osteoconductive bone adhesive biomaterial that bonds bone to bone and bone to metal. It is designed for use in dental and orthopedic applications, with ongoing clinical trials to validate its efficacy.
Regenerative Medicine
Biologics
Application Area
Battlefield Resuscitation
Key People
Chief Executive Officer, Founder
Chief Operations Officer & CFO
Chief Scientific Officer
Chief Executive Officer, Founder
Chief Operations Officer & CFO
Chief Scientific Officer
News & Updates
RevBio has received a $2.4 million NIH grant to conduct a first-in-human clinical trial for its regenerative bone adhesive for cranial flap fixation and has enrolled the first five patients.
RevBio has received a $2.4 million NIH grant to conduct a first-in-human clinical trial for its regenerative bone adhesive for cranial flap fixation and has enrolled the first five patients.